Skip to main content

Advertisement

SpringerLink
Log in

Virus-induced hepatocellular carcinoma with special emphasis on HBV

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is a common malignant tumor with high lethality, and the hepatitis B virus (HBV) is a chief cause. HBV can accelerate HCC via multiple mechanisms. First, HBV induces immune reactions that lead to repeated hepatic inflammation, fibrosis and a deficient immune microenvironment. Subsequently, HBV can modify host genes near the insertion point through DNA integration to cause host cell genome instability and to generate carcinogenic fusion proteins. Additionally, HBV expresses diverse active proteins, especially HBx and HBs, which have a range of transactivation functions such as regulation of apoptosis, interference with intracellular signaling pathways, and alteration of epigenetics. Currently, primary prevention measures for HBV-induced HCC focus on vaccination and antiviral treatment. Here, we report the epidemiology, the molecular mechanism and the progress in therapeutic strategies for controlling HBV-induced HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Croaqh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014;20(30):10395–10404

    Article  Google Scholar 

  2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108

    Article  PubMed  Google Scholar 

  3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(Suppl 3):S206–S214

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zhu RX, Seto WK, Lai CL, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver. 2016;10(3):332–339

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26(49):6266–6273

    Article  PubMed  Google Scholar 

  6. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36(5):1206–1213

    Article  CAS  PubMed  Google Scholar 

  7. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 2003;157(8):674–682

    Article  PubMed  Google Scholar 

  8. Sunbul Mustafa. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427–5434

    Article  PubMed  PubMed Central  Google Scholar 

  9. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13(12):2140–2151

    Article  PubMed  PubMed Central  Google Scholar 

  10. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–3044

    Article  CAS  PubMed  Google Scholar 

  11. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73

    Article  CAS  PubMed  Google Scholar 

  12. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494–1498

    Article  PubMed  PubMed Central  Google Scholar 

  13. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149

    Article  CAS  PubMed  Google Scholar 

  14. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–2380

    Article  CAS  PubMed  Google Scholar 

  15. Yang L, Karin M. Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ. 2014;21(11):1677–1686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Li W, Xiao J, Zhou X, et al. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. J Clin Invest. 2015;125(11):4239–4254

    Article  PubMed  PubMed Central  Google Scholar 

  17. Han Yi-Fang, Zhao Jun, Ma Li-Ye, et al. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17(38):4258–4270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T cell dysfunction and predicts poor prognosis in patients with HBV-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–1351

    Article  CAS  PubMed  Google Scholar 

  19. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology. 2013;57:183–194

    Article  CAS  PubMed  Google Scholar 

  20. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132(7):2328–2339

    Article  PubMed  Google Scholar 

  21. Zhang HH, Mei MH, Fei R, et al. Regulatory T cells in chronic hepatitis B patients affect the immune pathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010;17(Suppl 1):34–43

    Article  PubMed  Google Scholar 

  22. Yi Y, He HW, Wang JX, et al. The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner. J Hepatol. 2013;58(5):977–983

    Article  CAS  PubMed  Google Scholar 

  23. Liu Y, Xu L, Zeng Q, et al. Downregulation of FGL2/prothrombinase delays HCCLM6 xenografttumour growth and decreases tumour angiogenesis. Liver Int. 2012;32(10):1585–1595

    Article  CAS  PubMed  Google Scholar 

  24. Han M, Yan W, Guo W, et al. Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. J Biol Chem. 2008;283(47):32715–32729

    Article  CAS  PubMed  Google Scholar 

  25. Su K, Chen F, Yan WM, et al. Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. World J Gastroenterol. 2008;14(39):5980–5989

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wang M, Liu J, Xi D, et al. Adenovirus-mediated artificial miRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth. J Gene Med. 2016;18(7):102–111

    Article  CAS  PubMed  Google Scholar 

  27. Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–769

    Article  CAS  PubMed  Google Scholar 

  28. Tarocchi M, Polvani S, Marroncini G, et al. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014;20(33):11630–11640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78–88

    Article  CAS  PubMed  Google Scholar 

  30. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol. 2015;21(1):311–317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ding D, Lou X, Hua D, et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet. 2012;8(12):e1003065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44(7):760–764

    Article  CAS  PubMed  Google Scholar 

  33. Ali A, Abdel-Hafiz H, Suhail M, et al. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol. 2014;20(30):10238–10248

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78–88

    Article  CAS  PubMed  Google Scholar 

  35. Minor MM, Slagle BL. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. Viruses. 2014;6(11):4683–4702

    Article  PubMed  PubMed Central  Google Scholar 

  36. Shen L, Zhang X, Hu D, et al. Hepatitis B virus X (HBx) play an anti-apoptosis role in hepatic progenitor cells by activating Wnt/beta-catenin pathway. Mol Cell Biochem. 2013;383(1–2):213–222

    Article  CAS  PubMed  Google Scholar 

  37. Rawat S, Clippinger AJ, Bouchard MJ. Modulation of apoptotic signaling by the hepatitis B Virus X protein. Viruses. 2012;4(11):2945–2972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fan H, Zhang H, Pascuzzi PE, et al. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene. 2016;35(6):715–726

    Article  CAS  PubMed  Google Scholar 

  39. Tang S, Hu W, Hu J, et al. Hepatitis B virus X protein promotes P3 transcript expression of the insulin-like growth factor 2 gene via inducing hypomethylation of P3 promoter in hepatocellular carcinoma. Liver Int. 2015;35(2):608–619

    Article  CAS  PubMed  Google Scholar 

  40. Zhang H, Xing Z, Mani SK, et al. RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. Hepatology. 2016;64(4):1033–1048

    Article  PubMed  PubMed Central  Google Scholar 

  41. Wang DY, Zou LP, Liu XJ, et al. Hepatitis B virus X protein induces the histone H3 lysine 9 trimethylation on the promoter of p16 gene in hepatocarcinogenesis. Exp Mol Pathol. 2015;99(3):399–408

    Article  CAS  PubMed  Google Scholar 

  42. Guerrieri F, Belloni L, Pediconi N, et al. Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis. 2013;33(2):147–156

    Article  CAS  PubMed  Google Scholar 

  43. Zhang ZZ, Liu X, Wang DQ, et al. Hepatitis B virus and hepatocellular carcinoma at the miRNA level. World J Gastroenterol. 2011;17(28):3353–3358

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Li YW, Yang FC, Lu HQ, et al. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol. 2016;22(6):1943–1952

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Levrero Massimo, Zucman-Rossi Jessica. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–S101

    Article  CAS  PubMed  Google Scholar 

  46. Zhang X, Gao L, Liang X, et al. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes. Liver Int. 2015;35(3):1087–1094

    Article  CAS  PubMed  Google Scholar 

  47. Zhao J, Lawless MW. Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine. 2013;64:626–637

    Article  CAS  PubMed  Google Scholar 

  48. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855–1859

    Article  CAS  PubMed  Google Scholar 

  49. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–1355

    Article  CAS  PubMed  Google Scholar 

  50. Chang MH, You SL, Chen CJ, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology. 2016;151(3):472–480

    Article  CAS  PubMed  Google Scholar 

  51. Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in KhonKaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev. 2008;9(3):507–509

    PubMed  Google Scholar 

  52. Lanier AP, Holck P, Ehrsam Day G, et al. Childhood cancer among Alaska Natives. Pediatrics. 2003;112(5):e396

    Article  PubMed  Google Scholar 

  53. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422

    PubMed  Google Scholar 

  54. Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;. doi:10.1016/j.jhep.2016.07.025

    Google Scholar 

  55. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022

    Article  PubMed  PubMed Central  Google Scholar 

  56. EASL-EORTC. EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943

    Article  Google Scholar 

  57. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–474

    Article  PubMed  PubMed Central  Google Scholar 

  58. Tawada A, Kanda T, Imazeki F, et al. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int. 2016;10(4):574–593

    Article  PubMed  Google Scholar 

  59. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28(9):1067–1077

    Article  CAS  PubMed  Google Scholar 

  60. European Association for The Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943

    Article  Google Scholar 

  61. Qu LS, Liu JX, Kuai XL, et al. Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis. Hepatol Res. 2014;44(7):750–760

    Article  PubMed  Google Scholar 

  62. Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother. 2016;17(7):911–919

    Article  CAS  PubMed  Google Scholar 

  63. Zhang W, Song TQ, Zhang T, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2(6):1125–1134

    PubMed  PubMed Central  Google Scholar 

  64. Xu X, Huang P, Tian H, et al. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(6):1273–1278

    Article  CAS  PubMed  Google Scholar 

  65. Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100(2):376–382

    Article  CAS  PubMed  Google Scholar 

  66. Cholongitas E, Goulis J, Akriviadis E, et al. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transplant. 2011;17(10):1176–1190

    Article  Google Scholar 

  67. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338

    Article  CAS  PubMed  Google Scholar 

  68. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853

    Article  PubMed  Google Scholar 

  69. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022

    Article  PubMed  PubMed Central  Google Scholar 

  70. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390

    Article  CAS  PubMed  Google Scholar 

  71. Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellularcarcinoma and of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609–617

    Article  CAS  PubMed  Google Scholar 

  72. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354

    Article  CAS  PubMed  Google Scholar 

  73. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015;33(suppl; abstr LBA101)

  74. Chan SL, Wong AM, Lee K, et al. Personalized therapy for hepatocellular carcinoma: where are we now? Cancer Treat Rev. 2016;45:77–86

    Article  PubMed  Google Scholar 

  75. Kang J, Wang J, Cheng J, et al. Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance. Oncotarget. 2016;. doi:10.18632/oncotarget.10241

    Google Scholar 

  76. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7–10

    Article  PubMed  Google Scholar 

  77. Chen CL, Yang JY, Lin SF, et al. Slow decline of hepatitis B burden in general population: results from apopulation-based survey and longitudinal follow-up study in Taiwan. J Hepatol. 2015;63(2):354–363

    Article  PubMed  Google Scholar 

  78. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555

    Article  PubMed  Google Scholar 

  79. Lin SY, Toyoda H, Kumada T, et al. Molecular evolution and phylodynamics of acute hepatitis B virus in Japan. PLoS ONE. 2016;11(6):e0157103

    Article  PubMed  PubMed Central  Google Scholar 

  80. Tian Q, Jia J. Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. Hepatol Int. 2016;10(6):854–860

    Article  PubMed  Google Scholar 

  81. Darmawan E, Turyadi KE, Nursanty NK, et al. Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia. J Med Virol. 2015;87:199–207

    Article  CAS  PubMed  Google Scholar 

  82. Sunbul Mustafa. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427–5434

    Article  PubMed  PubMed Central  Google Scholar 

  83. Congly SE, Wong P, Al-Busafi SA, et al. Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres. Liver Int. 2013;33:1363–1369

    Article  CAS  PubMed  Google Scholar 

  84. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005;25(6):1097–1107

    Article  CAS  PubMed  Google Scholar 

  85. de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190–1200

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Mr. Muyang Yang for preparing the figure.

Author information

Authors and Affiliations

  1. Department of Infectious Disease, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, No 1095, Jiefang Avenue, Wuhan, 430030, China

    Ming Wang, Dong Xi & Qin Ning

Authors
  1. Ming Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qin Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qin Ning.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, M., Xi, D. & Ning, Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int 11, 171–180 (2017). https://doi.org/10.1007/s12072-016-9779-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-016-9779-5

Keywords

Search

Navigation